INT251777

Context Info Confidence 0.04 First Reported 2008 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 1 Disease Relevance 1.00 Pain Relevance 0.08

embryo development (PDGFA) DNA binding (TXK) cell-cell signaling (PDGFA) cytoplasm (TXK) extracellular space (PDGFA) extracellular region (PDGFA)

TXK (Homo sapiens) PDGFA (Homo sapiens)

Pain Link Frequency Relevance Heat headache 4 50.96 antagonist 1 50.24 Inflammation 5 5.00 peripheral neuropathy 2 5.00 Pain 2 5.00 tolerance 1 5.00 Potency 1 5.00

Disease Link Frequency Relevance Heat Breast Cancer 59 98.56 Lung Cancer 1 94.96 Advanced Or Metastatic Breast Cancer 84 86.80 Lymphatic System Cancer 1 69.52 Toxicity 14 53.84 Headache 4 50.96 Vomiting 13 50.56 Diarrhoea 14 50.24 Cancer 35 47.84 Disease 22 45.88

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Motesanib is a small molecule tyrosine kinase inhibitor of VEGF that targets VEGFR 1, 2, 3 and PDGF that has been evaluated in preclinical models in combination with either tamoxifen or docetaxel and was shown to have potential use in breast cancer.[68] A large phase II clinical trial is ongoing evaluating motesanib and paclitaxel in the treatment of breast cancer).[47]

Negative_regulation (inhibitor) of molecule tyrosine kinase Positive_regulation (targets) of PDGF associated with breast cancer

1) Confidence 0.04 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.00 Pain Relevance 0.08

General Comments

This test has worked.